Thiogenesis Therapeutics, Corp.
TTIPF
$0.44
$0.02897.03%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 16.20% | 28.11% | 22.64% | -26.23% | 23.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -39.15% | -18.19% | -22.67% | 267.80% | 50.91% |
| Operating Income | 39.15% | 18.19% | 22.67% | -267.80% | -50.91% |
| Income Before Tax | 38.74% | 26.53% | 33.17% | -364.04% | -45.35% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 38.74% | 26.53% | 33.17% | -364.04% | -45.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 38.74% | 26.53% | 33.17% | -364.04% | -45.35% |
| EBIT | 39.15% | 18.19% | 22.67% | -267.80% | -50.91% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 47.52% | 37.13% | 41.87% | -288.78% | -5.21% |
| Normalized Basic EPS | 47.62% | 37.50% | 41.73% | -325.00% | -5.00% |
| EPS Diluted | 47.52% | 37.13% | 41.87% | -288.78% | -5.21% |
| Normalized Diluted EPS | 47.62% | 37.50% | 41.73% | -325.00% | -5.00% |
| Average Basic Shares Outstanding | 17.08% | 17.07% | 14.99% | 19.52% | 37.61% |
| Average Diluted Shares Outstanding | 17.08% | 17.07% | 14.99% | 19.52% | 37.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |